Table I.
Patient characteristics.
| Category | Value |
|---|---|
| Age, yearsa | 63 (42–85) |
| Sexb | |
| Male | 40 (55.6%) |
| Female | 32 (44.4%) |
| Tumor diameter, mma | 30 (7–106) |
| Stageb | |
| Locally advanced | 20 (27.8%) |
| Metastatic | 52 (72.2%) |
| First-line regimenb | |
| GEM + nab-PTX | 16 (22.2%) |
| FOLFIRINOX | 10 (13.9%) |
| GEM | 44 (61.1%) |
| S-1 | 2 (2.8%) |
| CEA (ng/ml)a | 4.2 (1.2–1738.0) |
| CA19-9 (U/ml)a | 1326.1 (0.3–603000.2) |
| NLRa | 3.2 (1.2–11.6) |
| PLRa | 175.0 (63.9–547.1) |
| PNIa | 45.5 (32.4–60.7) |
| mGPSb | |
| 0 | 52 (72.2%) |
| 1 | 11 (15.3%) |
| 2 | 9 (12.5%) |
| CONUT scoreb | |
| 0–1 | 18 (27.3%) |
| 2–4 | 39 (59.1%) |
| 5–8 | 8 (12.1%) |
| 8< | 1 (1.5%) |
a
Data presented as the mean (range)
b
Data presented as the number of patients (%). GEM, gemcitabine; nab-PTX, nab-paclitaxel; CEA, carcinoembryonic antigen; CA19-9, cancer antigen 19-9; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; mGPS, modified Glasgow prognostic score; CONUT, controlling nutritional status.